医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Technavio Publishes New Industry Analysis on the Osteoporosis Drugs Market in BRIC Nations from 2015-2019

2015年10月08日 AM12:45
このエントリーをはてなブックマークに追加


 

LONDON

Technavio has published a new report on the osteoporosis drugs market in BRIC nations, which is expected to grow at a CAGR of over 17% from 2015-2019.

About the Report

According to the new report by Technavio, an overall assessment of the advantages and disadvantages of current osteoporosis treatment options presents the existence of unmet medical needs for the available drugs.

“Unmet medical need in terms of safety, efficacy, and compliance compels researchers to develop drugs that increase bone density, replace lost bone mass, and rebuild bone strength. For instance, Pfizer will likely lead the market during the forecast period through the sales of bazedoxifene, a third generation selective estrogen receptor modulator,” says Faisal Ghaus, Vice President of Technavio.

The latest report by Technavio also emphasizes the shift toward anabolic treatment, which are currently in the late and mid-stages of development.

“The treatment paradigm of osteoporosis has been stationary for the past few decades in the BRIC countries. Therefore, the launch of new efficacious and safe anabolic treatments will be the major modification in the management of osteoporosis,” adds Ghaus.

Market Scope and Calculation of Market Size

The new Technavio report covers the present scenario and growth prospects of the osteoporosis drugs market in BRIC nations from 2015-2019. To calculate the market size, we consider revenue generated from the sales of various branded and generic pharmaceutical products for treating osteoporosis.

Key Information Covered in the Report:

  • Key Vendors:

    • Amgen
    • Eli Lilly
    • Merck
    • Novartis
  • Market Growth Drivers:
  • Market Challenges:
  • Market Trends:

Technavio currently has more than 3000 market research reports on a huge range of topics, including 100+ reports on the osteoporosis drugs market:

If you are interested in more information, please contact our media team at media@technavio.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151007005045/en/

CONTACT

Technavio Research
Jesse Maida
US: +1-630-333-9501
UK:
+44-208-123-1770
Media & Marketing Executive
www.technavio.com
media@technavio.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表
  • Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
  • ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu neuartigem Antikörper-Wirkstoff-Konjugat ADCT-402